Literature DB >> 18719020

Characterization of thyrotropin receptor antibody-induced signaling cascades.

Syed A Morshed1, Rauf Latif, Terry F Davies.   

Abstract

The TSH receptor (TSHR) is constitutively active and is further enhanced by TSH ligand binding or by stimulating TSHR antibodies (TSHR-Abs) as seen in Graves' disease. TSH is known to activate the thyroid epithelial cell via both Galphas-cAMP/protein kinase A/ERK and Galphaq-Akt/protein kinase C coupled signaling networks. The recent development of monoclonal antibodies to the TSHR has enabled us to investigate the hypothesis that different TSHR-Abs may have unique signaling imprints that differ from TSH ligand itself. We have, therefore, performed sequential studies, using rat thyrocytes (FRTL-5, passages 5-20) as targets, to examine the signaling pathways activated by a series of monoclonal TSHR-Abs in comparison with TSH itself. Activation of key signaling molecules was estimated by specific immunoblots and/or enzyme immunoassays. Continuing constitutive TSHR activity in thyroid cells, deprived of TSH and serum for 48 h, was demonstrated by pathway-specific chemical inhibition. Under our experimental conditions, TSH ligand and TSHR-stimulating antibodies activated both Galphas and Galphaq effectors. Importantly, some TSHR-blocking and TSHR-neutral antibodies were also able to generate signals, influencing primarily the Galphaq effectors and induced cell proliferation. Most strikingly, antibodies that used the Galphaq cascades used c-Raf-ERK-p90RSK as a unique signaling cascade not activated by TSH. Our study demonstrated that individual TSHR-Abs had unique molecular signatures which resulted in sequential preferences. Because downstream thyroid cell signaling by the TSHR is both ligand dependent and independent, this may explain why TSHR-Abs are able to have variable influences on thyroid cell biology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18719020      PMCID: PMC2630889          DOI: 10.1210/en.2008-0878

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  58 in total

Review 1.  Cellular signaling: pivoting around PDK-1.

Authors:  A Toker; A C Newton
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 2.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

3.  Thyrotropin activates mitogen-activated protein kinase pathway in FRTL-5 by a cAMP-dependent protein kinase A-independent mechanism.

Authors:  L Iacovelli; L Capobianco; L Salvatore; M Sallese; G M D'Ancona; A De Blasi
Journal:  Mol Pharmacol       Date:  2001-11       Impact factor: 4.436

4.  Detection of functionally different types of pathological autoantibodies against thyrotropin receptor in Graves' patients sera by luminescent immunoprecipitation analysis.

Authors:  W B Minich; U Loos
Journal:  Exp Clin Endocrinol Diabetes       Date:  2000       Impact factor: 2.949

5.  Thyrotropin modifies activation of nuclear factor kappaB by tumour necrosis factor alpha in rat thyroid cell line.

Authors:  T Kikumori; F Kambe; T Nagaya; H Funahashi; H Seo
Journal:  Biochem J       Date:  2001-03-15       Impact factor: 3.857

6.  Activation of the small G protein Rap1 in dog thyroid cells by both cAMP-dependent and -independent pathways.

Authors:  S Dremier; F Vandeput; F J Zwartkruis; J L Bos; J E Dumont; C Maenhaut
Journal:  Biochem Biophys Res Commun       Date:  2000-01-07       Impact factor: 3.575

Review 7.  Thyrotropin-dependent proliferation of in vitro rat thyroid cell systems.

Authors:  D L Medina; P Santisteban
Journal:  Eur J Endocrinol       Date:  2000-08       Impact factor: 6.664

8.  Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms.

Authors:  A Balendran; G R Hare; A Kieloch; M R Williams; D R Alessi
Journal:  FEBS Lett       Date:  2000-11-10       Impact factor: 4.124

Review 9.  Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models.

Authors:  T Kimura; A Van Keymeulen; J Golstein; A Fusco; J E Dumont; P P Roger
Journal:  Endocr Rev       Date:  2001-10       Impact factor: 19.871

10.  Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody.

Authors:  Jane Sanders; Dimitri Y Chirgadze; Paul Sanders; Stuart Baker; Andrew Sullivan; Anshu Bhardwaja; Jane Bolton; Magnus Reeve; Nobuhiro Nakatake; Michele Evans; Tonya Richards; Michael Powell; Ricardo Núñez Miguel; Tom L Blundell; Jadwiga Furmaniak; Bernard Rees Smith
Journal:  Thyroid       Date:  2007-05       Impact factor: 6.568

View more
  52 in total

1.  How one TSH receptor antibody induces thyrocyte proliferation while another induces apoptosis.

Authors:  Syed A Morshed; Risheng Ma; Rauf Latif; Terry F Davies
Journal:  J Autoimmun       Date:  2013-08-17       Impact factor: 7.094

2.  Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor.

Authors:  Chris J van Koppen; Marcel E de Gooyer; Willem-Jan Karstens; Ralf Plate; Paolo G M Conti; Tanja A E van Achterberg; Monique G A van Amstel; Jolanda H G M Brands; Jesse Wat; Rob J W Berg; J Robert D Lane; Andre M M Miltenburg; C Marco Timmers
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 3.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

4.  Bioassays for TSH Receptor Antibodies: Quo Vadis?

Authors:  George J Kahaly
Journal:  Eur Thyroid J       Date:  2015-03

Review 5.  TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy.

Authors:  Terry J Smith
Journal:  Nat Rev Endocrinol       Date:  2015-01-06       Impact factor: 43.330

6.  Emerging pharmacotherapy for treatment of Graves' disease.

Authors:  Rebecca S Bahn
Journal:  Expert Rev Clin Pharmacol       Date:  2012-11       Impact factor: 5.045

7.  The differences in T and B cell subsets in thyroid of children with Graves' disease and Hashimoto's thyroiditis.

Authors:  Iwona Ben-Skowronek; Leszek Szewczyk; Beata Kulik-Rechberger; Elzbieta Korobowicz
Journal:  World J Pediatr       Date:  2013-01-18       Impact factor: 2.764

Review 8.  IGF1 receptor and thyroid-associated ophthalmopathy.

Authors:  Michelle Mohyi; Terry J Smith
Journal:  J Mol Endocrinol       Date:  2017-12-22       Impact factor: 5.098

Review 9.  Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies.

Authors:  Terry F Davies; Rauf Latif
Journal:  Expert Opin Ther Targets       Date:  2015-03-13       Impact factor: 6.902

10.  A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.

Authors:  Adina F Turcu; Seema Kumar; Susanne Neumann; Michael Coenen; Seethalakshmi Iyer; Pamela Chiriboga; Marvin C Gershengorn; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2013-03-12       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.